Ocular Therapeutix (NASDAQ:OCUL) shares tumbled 25% Tuesday following mixed results from its Phase 3 SOL-1 trial for Axpaxli in wet age-related macular degeneration. While the drug met its primary endpoint with 74.1% of patients maintaining visual acuity at 36 weeks compared to 55.8% for Regeneron's Eylea, investors focused on the stronger-than-expected control arm performance and smaller-than-anticipated efficacy gap.

The trial showed Axpaxli patients maintained vision at 65.9% versus 44.2% for Eylea at 52 weeks, representing a 21.7% observed difference. Despite statistical significance, market reaction suggested disappointment over the high control arm response and minimal visual acuity improvement among rescue-free patients. The safety profile revealed higher incidences of vitreous floaters and cataracts in the Axpaxli group compared to Eylea.

Analysts offered divided perspectives on the long-term implications. TD Cowen's Tara Bancroft noted the impressive data in rescue-free patients, while RBC's Lisa Walter suggested investors might be initially disappointed by the results. Needham's Serge Belanger raised questions about Axpaxli's durability compared to newer competitors like Eylea HD and Vabysmo. The market reaction reflects heightened expectations for breakthrough efficacy in the competitive AMD treatment landscape.